- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03479255
Smartstep Smartphone PAD (SMARTSTEP)
Smartphone-Enabled Supervised Exercise Therapy for the Treatment of Symptomatic Peripheral Arterial Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Amit Shah, MD
- Phone Number: 404-727-8712
- Email: ajshah3@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Recruiting
- Grady Health System (non-CRN)
-
Contact:
- Amit Shah, MD
- Phone Number: 404-727-8712
- Email: ajshah3@emory.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinically stable intermittent claudication
- Able to give informed consent
- Age 18-89 years
And one of the following:
- ABI < 0.9 after 10 minutes of rest OR
- For subjects with an ABI of >1.3 (non-compressible arteries) a Toe-Brachial Index (TBI) of < 0.70 must be obtained for subject qualification. If ABI is > 0.9 to 1.0, a reduction of 20% in ABI must be measured within 1 minute of treadmill testing.
Exclusion Criteria:
Life-threatening process including:
- Sepsis
- Critical limb ischemia (Rutherford class 4-6)
- Unstable angina
- Active malignancy with life expectancy < 6 months
- Severe NYHA Class IV heart failure
Condition other than PAD that limits walking before claudication onset
This includes, but is not limited to:
- Severe angina or dyspnea
- Arthritis
- Muscle weakness/pain
Active behavioral conditions such as uncontrolled schizophrenia or illicit drug addiction that, in the opinion of the study team, will interfere with active participation
Inability to attend study visits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Smartphone-enabled structured exercise therapy (SE-SET)
This arm involves a smartphone app Movn - rehabilitation platform based on MULTIFIT, a case-management system for secondary prevention and patient surveillance after acute MI. The key features of the smartphone app include daily reminders to exercise, virtual diary for patients to enter data on exercise sessions, two-way secure messaging with the health coach, and educational videos on heart and vascular health. |
The SE-SET program lasts a total of 12 weeks per participant.
During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight, and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education.
Patients will be contacted by a member of the study team weekly via phone call in order to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patient from being active, high BP/weight issues) and help patients navigate those barriers.
Movn participants can also send direct messages to the study team to ask about non-urgent issues related to their care.
|
Active Comparator: Standard exercise therapy
Self-directed, unsupervised exercise as prescribed by the patient's physician.
|
The Standard exercise therapy lasts a total of 12 weeks per participant.
Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education.
These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in 6-minute walk test (6MWT) distance completed
Time Frame: Immediately before and after the 12-week period
|
The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance.
The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
|
Immediately before and after the 12-week period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Walking Impairment Questionnaire (WIQ) score
Time Frame: Immediately before and after the 12-week period
|
WIQ measures self-reported walking distance, speed, and stair-climbing ability.
In the WIQ distance score, the participant is asked to assess the degree of walking difficulty in walking specific distances on a scale from 0 to 4. A score of 0 represents the inability to walk the distance and a score of 4 represents no difficulty.
WIQ speed score assesses the degree of difficulty in walking one block at specific speeds, ranging from walking slowly to jogging, on a scale of 0 to 4. In the WIQ stair-climbing score, the participant is asked to report the degree of difficulty climbing specific numbers of flights of stairs, ranging from one to three flights of stairs, on a scale of 0 to 4. This graded score is multiplied by a prespecified weight for each distance, speed, or number of stair flights.
The products are summed and divided by the maximum possible score to obtain a percent score, ranging from 0 (inability to perform any of the tasks) to 100 (representing no difficulty).
|
Immediately before and after the 12-week period
|
Change in Physical Health Composite Score of SF-36
Time Frame: Immediately before and after the 12-week period
|
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
To calculate the scores it is necessary to use special software.
The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.
|
Immediately before and after the 12-week period
|
Change in claudication onset time during 6MWT
Time Frame: Immediately before and after the 12-week period
|
One typical symptom of peripheral arterial occlusive disease' (PAOD) is claudication , which is defined as pain, cramps, numbness or a sense of fatigue in the muscles associated with walking, in one or both lower limbs, affecting either the distal or proximal muscle groups.
|
Immediately before and after the 12-week period
|
Change in ankle-brachial pressure index (ABPI)
Time Frame: Immediately before and after the 12-week period
|
The ankle-brachial pressure index (ABPI) is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm (brachium).
Compared to the arm, lower blood pressure in the leg suggests blocked arteries due to peripheral artery disease (PAD).
The ABPI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressure in the arm.
|
Immediately before and after the 12-week period
|
Change in number of steps/week
Time Frame: Immediately before and after the 12-week period
|
Number of steps/week will be obtained from participants' fitness trackers
|
Immediately before and after the 12-week period
|
Critical Limb Ischemia
Time Frame: Over the 12-week study period
|
Number of Critical Limb Ischemia events reported by participants
|
Over the 12-week study period
|
Other Cardiovascular Outcomes
Time Frame: Over the 12-week study period
|
Number of Cardiovascular Outcomes other than Critical Limb Ischemia events reported by participants
|
Over the 12-week study period
|
Exercise-Related Injury
Time Frame: Over the 12-week study period
|
Number of Exercise-Related Injury events reported by participants
|
Over the 12-week study period
|
Mortality
Time Frame: Over the 12-week study period
|
Number of deaths
|
Over the 12-week study period
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amit Shah, MD, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00102543
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Smartphone-enabled structured exercise therapy (SE-SET)
-
University of California, San FranciscoNational Institute of Mental Health (NIMH)CompletedHIV Infections | Acquired Immunodeficiency SyndromeUnited States
-
Riphah International UniversityRecruiting
-
Goethe UniversityKing's College London; Radboud University Medical Center; Heidelberg University; Hospital Vall d'HebronCompletedDepression | Obesity | Attention-Deficit / Hyperactivity DisorderGermany, Netherlands, Spain, United Kingdom
-
Maharishi Markendeswar University (Deemed to be...Not yet recruitingPolycystic Ovary Syndrome | Anti-Mullerian Hormone Deficiency | Female Infertility EndocrineIndia
-
University Magna GraeciaCompletedPolycystic Ovary Syndrome | AnovulationItaly